Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System
Rhea-AI Summary
Stereotaxis (NYSE:STXS), a pioneer in surgical robotics, announced that Erasmus Medical Center in Rotterdam has successfully performed its first procedures using the Genesis Robotic Magnetic Navigation System. Erasmus MC, having completed over 4,500 procedures with Stereotaxis technology, becomes the first center in The Netherlands to implement this advanced system.
The Genesis System represents the latest advancement in Robotic Magnetic Navigation technology, designed to treat arrhythmias through cardiac ablation. Dr. Sing-Chien Yap, Director of Electrophysiology at Erasmus Medical Center, highlighted the system's enhanced speed and responsiveness, particularly when combined with the MAGiC Catheter, benefiting patients with complex arrhythmias, including children and those with congenital heart disease.
Positive
- First successful implementation of Genesis System in The Netherlands, expanding market presence
- Strong track record with over 4,500 procedures performed at Erasmus MC using Stereotaxis technology
- Technology demonstrates enhanced capabilities when combined with MAGiC Catheter
- System shows versatility in treating complex cases including pediatric and congenital heart disease patients
Negative
- Significant dependence on third-party vendors as disclosed in risk factors
- Purchase orders subject to contingencies and potential modifications or cancellations
News Market Reaction
On the day this news was published, STXS gained 2.49%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.3% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $280M at that time. Trading volume was elevated at 2.0x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
ST. LOUIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced successful first procedures by physicians at Erasmus University Medical Center in Rotterdam, The Netherlands, using the advanced Genesis Robotic Magnetic Navigation System.
“We have long recognized the clinical benefits of robotics, and are delighted to be the first in The Netherlands to make the Genesis robotic system available to cardiovascular patients,” said Dr. Sing-Chien Yap, Director of Electrophysiology at Erasmus Medical Center. “We are impressed with the speed and responsiveness of Genesis. Combined with the MAGiC Catheter we are particularly pleased with the synergistic additive improvements to robotic magnetic navigation. These technological advances are important in ensuring we can offer the best care to all arrhythmia patients, including children, patients with congenital heart disease, and patients with complex arrhythmia.”
Erasmus MC has been a global leader in using robotic magnetic navigation for complex arrhythmia procedures, having performed over 4,500 procedures with Stereotaxis technology. The Genesis System is the latest advancement in Robotic Magnetic Navigation technology. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmia may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.
“We appreciate our long-term partnership with the electrophysiology team at Erasmus,” said David Fischel, Stereotaxis Chairman and CEO. “We look forward to continuing to support their successful robotic program and working together to advance technological progress, scientific discovery, and clinical care.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
What is the significance of Erasmus Medical Center adopting Stereotaxis (STXS) Genesis Robotic System?
How does the Stereotaxis (STXS) Genesis System benefit cardiac patients?
What is the market potential for Stereotaxis (STXS) Genesis Robotic System?
How many procedures has Stereotaxis (STXS) technology been used for globally?
What are the key features of Stereotaxis (STXS) Genesis Robotic System at Erasmus MC?
